top of page
Licensed Ophthalmology Program
AMD101 topical ophthalmic technology has been exclusively licensed to NeoVascularX, Inc. for global clinical development and commercialization. The lead clinical candidate is being developed as NVX-101.
Active ingredient
Small molecule compound which has been safe in human for more than 30 years
Target indication
Age-related Macular degeneration (AMD)
Patients with AMD lose vision acuity. More than 3 million patients suffer from AMD in US.
MOA
Inhibition of VEGF and neovascularization
![AMD-OCT[1].jpg](https://static.wixstatic.com/media/e39661_375e71a095fe4f9d99226499bc655792~mv2.jpg/v1/fill/w_253,h_152,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/AMD-OCT%5B1%5D.jpg)
Pre-clinical model efficacy
Highly specific inhibition of neovascularization in the back of the eye.
Delivery to the back of the eye
An order of magnitude greater than effective dose of the active ingredient was delivered to the back of the eyes by topical application in rabbits and monkeys.
Current therapies
Current standard-of-care treatments for neovascular AMD include intravitreal anti-VEGF agents. AMD101/NVX-101 is being developed as a topical ophthalmic therapeutic with the goal of reducing the treatment burden associated with repeated intraocular injections, subject to successful clinical development and regulatory approval.
Patents
Dec 2023 US patent for AMD101 topical ophthalmic products issued.
Dec 2023 A new PCT patent application for AMD101 topical products published.
Jun 2022 A new PCT patent application for AMD101 topical products published.
Apr 2021 Japan patent of AMD101 topical ophthalmic products issued.
Investigational Product Disclaimer
AMD101/NVX-101 are investigational product candidates and have not been approved by the U.S. Food and Drug Administration or other regulatory authorities for the indications described. Their safety and efficacy for these investigational uses have not been established.
bottom of page